Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Sacituzumab Govitecan · Trodelvy, GS-0132

Antibody-drug conjugate · Cytotoxic, directed at Trop-2 (tumor-associated calcium signal transducer 2) (TACSTD2) · developed by Immunomedics

Approved FDA, Apr 2020
GILD Developer
5 Registered trials

What is Sacituzumab Govitecan?

Sacituzumab govitecan is an antibody-drug conjugate in which a humanized anti-Trop-2 antibody is linked to SN-38, a topoisomerase I inhibitor. After binding Trop-2-expressing cancer cells and being internalized, SN-38 is released and causes DNA damage that leads to cell death. It is studied in urothelial carcinoma, thyroid cancers, thymic tumors and triple-negative breast cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Trodelvy, GS-0132, IMMU-132
Drug type
Antibody-drug conjugate
Targets
Trop-2 (tumor-associated calcium signal transducer 2) (TACSTD2), topoisomerase I (TOP1) (secondary target)
Mechanism
Cytotoxic, directed at Trop-2 (tumor-associated calcium signal transducer 2) (TACSTD2)
Pathways
DNA damage response, apoptosis
Therapy area
Oncology
Developer
Immunomedics Inc (GILD)
Also in trials of
VERU
FDA status
Approved as Trodelvy (April 22, 2020), BLA761115 · FDA label
UNII
M9BYU8XDQ6

✅ FDA-approved uses

From the indications section of the FDA label (version of Jun 24, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05633654 Phase 3 Triple Negative Breast Cancer Recruiting GILD
NCT06235216 Phase 2 Differentiated Thyroid Cancer Recruiting GILD
NCT06248515 Phase 2 Thymoma Recruiting GILD
NCT05327530 Phase 2 Locally Advanced or Metastatic Urothelial Carcinoma Active not recruiting GILD
NCT05008510 Phase 2 Metastatic Triple Negative Breast Cancer Withdrawn VERU

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Anaplastic Thyroid CancerDifferentiated Thyroid CancerLocally Advanced or Metastatic Urothelial CarcinomaThymic CarcinomaThymomaTriple Negative Breast CancerMetastatic Triple Negative Breast Cancer

Other drugs acting on TACSTD2

Datopotamab Deruxtecan FDA approved PBI-410 Phase 1/2 Sacituzumab Tirumotecan Phase 3

More from Immunomedics

Axicabtagene Ciloleucel FDA approved Bictegravir FDA approved Brexucabtagene Autoleucel FDA approved Bulevirtide FDA approved Cobicistat FDA approved Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDA approved Emtricitabine And Tenofovir Alafenamide FDA approved Emtricitabine/Tenofovir Disoproxil FDA approved Lenacapavir FDA approved Remdesivir FDA approved Seladelpar FDA approved Tenofovir Disoproxil FDA approved

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the GILD page.

Follow GILD, the company behind Sacituzumab Govitecan

See GILD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

GILD catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.